PET imaging utilizing 89Zr-labeled human antibody variant and theranostic technologies provided by a novel DDS carrier

Research output: Contribution to journalArticle

Abstract

“Theranostics”represents a ground-breaking concept of medical modality featuring a hybrid of therapeutic and diagnostic systems. We have recently fabricated a 2 7 kDa single chain variable fragment (scFv, which is essentially a humanized and shortened variant of IgG to establish clinically-applicable PET imaging and theranostics in cancer medicine. A target molecule is mesothelin, a 40 kDa-tumor differentiation-related cell surface glycoprotein antigen, that is frequently expressed by malignant tumors. The theranostics system which comprises of a novel 89 Zr-labeled drug delivery system (DDS), derived from novel biodegradable polymeric micelle, “Lactosome”, conjugated with specific scFv, aims to successfully deliver therapeutically effective molecules, such as, apoptosis-inducing small interfering RNA (siRNA), into targeted cells and to offer simultaneous visualization of targets via PET imaging. In particular, the combination of photodynamic therapy (PDT) with 5 -aminolevulinic acid (ALA) and photo-controlled intracellular siRNA delivery system further offers a promising theranostic-based system, ideally via its targeted apoptosis-inducing feature.

Original languageEnglish
Pages (from-to)214-222
Number of pages9
JournalDrug Delivery System
Volume33
Issue number3
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Drug Delivery Systems
Technology
Small Interfering RNA
Antibodies
Apoptosis
Single-Chain Antibodies
Neoplasms
Aminolevulinic Acid
Membrane Glycoproteins
Photochemotherapy
Micelles
Surface Antigens
Immunoglobulin G
Medicine
Theranostic Nanomedicine
Therapeutics

Keywords

  • Accelerated blood clearance (ABC)
  • Antibody variant (single chain variable fragment ScFv)
  • Drug delivery system (DDS)
  • PET imaging
  • Photodynamic therapy (PDT)
  • Theranostics (combined therapeutic and diagnostic technology)

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

@article{71c5501ec1d94350b9081167fa7172cb,
title = "PET imaging utilizing 89Zr-labeled human antibody variant and theranostic technologies provided by a novel DDS carrier",
abstract = "“Theranostics”represents a ground-breaking concept of medical modality featuring a hybrid of therapeutic and diagnostic systems. We have recently fabricated a 2 7 kDa single chain variable fragment (scFv, which is essentially a humanized and shortened variant of IgG to establish clinically-applicable PET imaging and theranostics in cancer medicine. A target molecule is mesothelin, a 40 kDa-tumor differentiation-related cell surface glycoprotein antigen, that is frequently expressed by malignant tumors. The theranostics system which comprises of a novel 89 Zr-labeled drug delivery system (DDS), derived from novel biodegradable polymeric micelle, “Lactosome”, conjugated with specific scFv, aims to successfully deliver therapeutically effective molecules, such as, apoptosis-inducing small interfering RNA (siRNA), into targeted cells and to offer simultaneous visualization of targets via PET imaging. In particular, the combination of photodynamic therapy (PDT) with 5 -aminolevulinic acid (ALA) and photo-controlled intracellular siRNA delivery system further offers a promising theranostic-based system, ideally via its targeted apoptosis-inducing feature.",
keywords = "Accelerated blood clearance (ABC), Antibody variant (single chain variable fragment ScFv), Drug delivery system (DDS), PET imaging, Photodynamic therapy (PDT), Theranostics (combined therapeutic and diagnostic technology)",
author = "Fumiaki Takenaka and Kazuko Kobayashi and Shunsaku Kimura and Eiichi Ozeki and Takashi Ohtsuki and Hirotsugu Kobuchi and Eiji Matsuura",
year = "2018",
month = "1",
day = "1",
doi = "10.2745/dds.33.214",
language = "English",
volume = "33",
pages = "214--222",
journal = "Drug Delivery System",
issn = "0913-5006",
publisher = "Japan Society of Drug Delivery System",
number = "3",

}

TY - JOUR

T1 - PET imaging utilizing 89Zr-labeled human antibody variant and theranostic technologies provided by a novel DDS carrier

AU - Takenaka, Fumiaki

AU - Kobayashi, Kazuko

AU - Kimura, Shunsaku

AU - Ozeki, Eiichi

AU - Ohtsuki, Takashi

AU - Kobuchi, Hirotsugu

AU - Matsuura, Eiji

PY - 2018/1/1

Y1 - 2018/1/1

N2 - “Theranostics”represents a ground-breaking concept of medical modality featuring a hybrid of therapeutic and diagnostic systems. We have recently fabricated a 2 7 kDa single chain variable fragment (scFv, which is essentially a humanized and shortened variant of IgG to establish clinically-applicable PET imaging and theranostics in cancer medicine. A target molecule is mesothelin, a 40 kDa-tumor differentiation-related cell surface glycoprotein antigen, that is frequently expressed by malignant tumors. The theranostics system which comprises of a novel 89 Zr-labeled drug delivery system (DDS), derived from novel biodegradable polymeric micelle, “Lactosome”, conjugated with specific scFv, aims to successfully deliver therapeutically effective molecules, such as, apoptosis-inducing small interfering RNA (siRNA), into targeted cells and to offer simultaneous visualization of targets via PET imaging. In particular, the combination of photodynamic therapy (PDT) with 5 -aminolevulinic acid (ALA) and photo-controlled intracellular siRNA delivery system further offers a promising theranostic-based system, ideally via its targeted apoptosis-inducing feature.

AB - “Theranostics”represents a ground-breaking concept of medical modality featuring a hybrid of therapeutic and diagnostic systems. We have recently fabricated a 2 7 kDa single chain variable fragment (scFv, which is essentially a humanized and shortened variant of IgG to establish clinically-applicable PET imaging and theranostics in cancer medicine. A target molecule is mesothelin, a 40 kDa-tumor differentiation-related cell surface glycoprotein antigen, that is frequently expressed by malignant tumors. The theranostics system which comprises of a novel 89 Zr-labeled drug delivery system (DDS), derived from novel biodegradable polymeric micelle, “Lactosome”, conjugated with specific scFv, aims to successfully deliver therapeutically effective molecules, such as, apoptosis-inducing small interfering RNA (siRNA), into targeted cells and to offer simultaneous visualization of targets via PET imaging. In particular, the combination of photodynamic therapy (PDT) with 5 -aminolevulinic acid (ALA) and photo-controlled intracellular siRNA delivery system further offers a promising theranostic-based system, ideally via its targeted apoptosis-inducing feature.

KW - Accelerated blood clearance (ABC)

KW - Antibody variant (single chain variable fragment ScFv)

KW - Drug delivery system (DDS)

KW - PET imaging

KW - Photodynamic therapy (PDT)

KW - Theranostics (combined therapeutic and diagnostic technology)

UR - http://www.scopus.com/inward/record.url?scp=85055811762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055811762&partnerID=8YFLogxK

U2 - 10.2745/dds.33.214

DO - 10.2745/dds.33.214

M3 - Article

AN - SCOPUS:85055811762

VL - 33

SP - 214

EP - 222

JO - Drug Delivery System

JF - Drug Delivery System

SN - 0913-5006

IS - 3

ER -